JP2009518005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518005A5 JP2009518005A5 JP2008542473A JP2008542473A JP2009518005A5 JP 2009518005 A5 JP2009518005 A5 JP 2009518005A5 JP 2008542473 A JP2008542473 A JP 2008542473A JP 2008542473 A JP2008542473 A JP 2008542473A JP 2009518005 A5 JP2009518005 A5 JP 2009518005A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hybridoma cell
- produced
- cell line
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 10
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 10
- 210000004408 hybridoma Anatomy 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 238000012286 ELISA Assay Methods 0.000 claims 2
- 102000004473 OX40 Ligand Human genes 0.000 claims 2
- 108010042215 OX40 Ligand Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73965905P | 2005-11-25 | 2005-11-25 | |
| US60/739,659 | 2005-11-25 | ||
| PCT/US2006/045522 WO2007062245A2 (en) | 2005-11-25 | 2006-11-27 | Human monoclonal antibody human cd134 (ox40) and methods of making and using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013161779A Division JP5802245B2 (ja) | 2005-11-25 | 2013-08-02 | ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009518005A JP2009518005A (ja) | 2009-05-07 |
| JP2009518005A5 true JP2009518005A5 (OSRAM) | 2010-01-14 |
| JP5476517B2 JP5476517B2 (ja) | 2014-04-23 |
Family
ID=38067974
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542473A Active JP5476517B2 (ja) | 2005-11-25 | 2006-11-27 | ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法 |
| JP2013161779A Active JP5802245B2 (ja) | 2005-11-25 | 2013-08-02 | ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013161779A Active JP5802245B2 (ja) | 2005-11-25 | 2013-08-02 | ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8283450B2 (OSRAM) |
| EP (4) | EP4219557A1 (OSRAM) |
| JP (2) | JP5476517B2 (OSRAM) |
| KR (1) | KR101340699B1 (OSRAM) |
| CN (1) | CN101331150B (OSRAM) |
| AU (1) | AU2006318329B2 (OSRAM) |
| CA (1) | CA2631015C (OSRAM) |
| DK (1) | DK3345927T5 (OSRAM) |
| ES (3) | ES2602263T5 (OSRAM) |
| FI (1) | FI3345927T3 (OSRAM) |
| HU (3) | HUE061960T2 (OSRAM) |
| LT (1) | LT3345927T (OSRAM) |
| PL (3) | PL3345927T3 (OSRAM) |
| PT (3) | PT3098238T (OSRAM) |
| SI (1) | SI3345927T1 (OSRAM) |
| TW (1) | TWI461436B (OSRAM) |
| WO (1) | WO2007062245A2 (OSRAM) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| AU2008219666A1 (en) * | 2007-02-27 | 2008-09-04 | Genentech, Inc. | Antagonist OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| US20090022720A1 (en) * | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
| AU2014202213B2 (en) * | 2007-12-14 | 2016-05-12 | Bristol-Myers Squibb Company | Binding Molecules to the Human OX40 Receptor |
| AU2016203429B2 (en) * | 2007-12-14 | 2018-01-25 | Bristol-Myers Squibb Company | Binding Molecules to the Human OX40 Receptor |
| SG186656A1 (en) * | 2007-12-14 | 2013-01-30 | Bristol Myers Squibb Co | Binding molecules to the human ox40 receptor |
| AU2010216152B2 (en) * | 2009-02-17 | 2015-05-14 | Ucb Biopharma Sprl | Antibody molecules having specificity for human OX40 |
| EA029793B1 (ru) | 2010-08-23 | 2018-05-31 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела к ох40 и способы их применения |
| CN103429261A (zh) * | 2010-12-22 | 2013-12-04 | 塞法隆澳大利亚股份有限公司 | 半寿期改进的修饰抗体 |
| CN116063522A (zh) * | 2011-06-13 | 2023-05-05 | 美国全心医药生技股份有限公司 | 抗psgl-1抗体及其用途 |
| BR112014000630A2 (pt) * | 2011-07-11 | 2017-02-14 | Glenmark Pharmaceuticals Sa | anticorpo antagonista ou fragmento do mesmo que se liga a uma ox40 humana, epítopo sobre o domínio extracelular ox40 humano, ácido nucleíco isolado, vetor, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição imunoconjugado, método para tratar um distúrbio mediado por ox40 em um indivíduo, uso de um anticorpo ou fragmento do mesmo, artigo de manufatura, kit e método para classificação in vitro |
| CA2845810C (en) * | 2011-08-23 | 2017-03-28 | Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| US10259626B2 (en) | 2012-03-08 | 2019-04-16 | Selig Sealing Products, Inc. | Container sealing member with protected security component and removal tab |
| DK2822592T3 (en) | 2012-03-08 | 2018-10-15 | Ludwig Institute For Cancer Res Limited | TGF-1-SPECIFIC ANTIBODIES AND PROCEDURES AND APPLICATIONS THEREOF |
| US9650411B2 (en) | 2012-08-07 | 2017-05-16 | Kyowa Hakko Kirin Co., Ltd. | Method of purifying protein |
| DK2925350T3 (da) | 2012-12-03 | 2019-05-13 | Bristol Myers Squibb Co | Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner |
| EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
| KR20160006168A (ko) * | 2013-03-18 | 2016-01-18 | 바이오서오엑스 프로덕스 비.브이. | 인간화 항-cd134(ox40) 항체 및 이의 용도 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| EP3632934A1 (en) * | 2014-03-31 | 2020-04-08 | F. Hoffmann-La Roche AG | Anti-ox40 antibodies and methods of use |
| RU2016142476A (ru) * | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| SMT202100116T1 (it) | 2014-05-28 | 2021-05-07 | Agenus Inc | Anticorpi anti-gitr e metodi di utilizzo degli stessi |
| BR112016027845A2 (pt) * | 2014-05-29 | 2017-10-31 | Medimmune Llc | proteínas de fusão de ox40l e usos das mesmas |
| CN107074951B (zh) | 2014-08-04 | 2021-08-03 | 贝勒研究院 | 拮抗性抗-ox40l抗体及其使用方法 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| ES2937020T3 (es) | 2015-03-03 | 2023-03-23 | Kymab Ltd | Anticuerpos, usos y métodos |
| TWI716405B (zh) * | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| LT3303396T (lt) | 2015-05-29 | 2023-01-10 | Bristol-Myers Squibb Company | Antikūnai prieš ox40 ir jų panaudojimo būdai |
| CN106699888B (zh) | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| CN107922912B (zh) * | 2015-08-10 | 2021-07-20 | 国立大学法人富山大学 | 抗原特异性单克隆抗体制作方法 |
| CA2999369C (en) * | 2015-09-22 | 2023-11-07 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
| KR20180053674A (ko) | 2015-10-02 | 2018-05-23 | 에프. 호프만-라 로슈 아게 | 공자극 tnf 수용체에 특이적인 이중특이성 항체 |
| CN114380908B (zh) * | 2015-10-15 | 2023-03-17 | 苏州丁孚靶点生物技术有限公司 | 抗ox40抗体及其应用 |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| CN105483083B (zh) * | 2016-01-20 | 2018-10-23 | 北京医明佳和生物科技有限公司 | 双阴性t细胞的转化扩增方法 |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| CN107815465B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| US11279948B2 (en) | 2016-08-31 | 2022-03-22 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric OX40 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| KR20210157471A (ko) * | 2016-12-15 | 2021-12-28 | 애브비 바이오테라퓨틱스 인크. | 항-ox40 항체 및 이의 용도 |
| CN108623686A (zh) * | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| CN108623685B (zh) * | 2017-03-25 | 2022-07-01 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| KR102769109B1 (ko) | 2017-11-24 | 2025-02-18 | 유큐(베이징) 바이오파마 코., 엘티디 | 항―ｏｘ４０ 항체 및 그의 용도 |
| WO2019156566A1 (en) | 2018-02-12 | 2019-08-15 | Umc Utrecht Holding B.V. | Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain |
| CN110467674B (zh) * | 2018-05-11 | 2022-05-31 | 同润澳门一人有限公司 | 抗ox40的全人抗体及其制备方法和用途 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020016417A1 (en) | 2018-07-19 | 2020-01-23 | Ichnos Sciences S.A. | Liquid antibody formulation |
| EP3860653A1 (en) | 2018-10-05 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| US10442866B1 (en) * | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| EP3997125A1 (en) * | 2019-07-08 | 2022-05-18 | New York University | Tumor immunotherapy using sindbis viral vectors and agonist monoclonal antibodies |
| EP4006047A1 (en) | 2019-07-31 | 2022-06-01 | Kyowa Kirin Co., Ltd. | Method for purifying antibody using adsorbent |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| JP7755581B2 (ja) | 2019-12-17 | 2025-10-16 | アムジエン・インコーポレーテツド | 治療における使用のためのデュアルインターロイキン－２／ｔｎｆ受容体アゴニスト |
| CN115803343A (zh) * | 2020-05-26 | 2023-03-14 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| WO2022075476A1 (en) * | 2020-10-09 | 2022-04-14 | Kyowa Kirin Co., Ltd. | Method for treating ox40 related disease |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| CN117529500A (zh) * | 2021-05-27 | 2024-02-06 | 柳韩洋行 | Ox40激动剂及其用途 |
| WO2022258606A1 (en) | 2021-06-07 | 2022-12-15 | Gadeta B.V. | Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| EP4507779A1 (en) | 2022-04-14 | 2025-02-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| WO2023227594A1 (en) | 2022-05-24 | 2023-11-30 | Gadeta Bv | Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof |
| WO2023237541A1 (en) | 2022-06-07 | 2023-12-14 | Gadeta B.V. | Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
| WO2024013401A1 (en) | 2022-07-15 | 2024-01-18 | Gadeta B.V. | Novel method for identifying gamma t-cell (or delta t-cell) receptor chains (or gammadelta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
| JP2025532464A (ja) | 2022-09-15 | 2025-10-01 | アビディキュア アイピー ビー．ブイ． | Ｎｋ細胞の腫瘍標的化のための多重特異性抗原結合タンパク質及びその使用 |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024100136A1 (en) | 2022-11-08 | 2024-05-16 | Gadeta B.V. | Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN116036268A (zh) * | 2023-03-02 | 2023-05-02 | 中南大学湘雅二医院 | 一种ox40l单克隆阻断抗体的应用 |
| WO2025161898A1 (en) * | 2024-02-02 | 2025-08-07 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-ox40 antibodies and uses thereof |
| WO2025186778A1 (en) | 2024-03-08 | 2025-09-12 | Janssen Biotech, Inc. | Combinations of oncolytic viruses and immunomodulators |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| CH668554A5 (de) | 1984-04-09 | 1989-01-13 | Sandoz Ag | Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung. |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| ES2039203T3 (es) | 1985-11-22 | 1993-09-16 | Takeda Chemical Industries, Ltd. | Composicion de liposomas. |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP2666345B2 (ja) | 1987-04-16 | 1997-10-22 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0448650A4 (en) | 1989-02-01 | 1992-05-13 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| JPH06500923A (ja) | 1990-09-21 | 1994-01-27 | カイロン コーポレイション | パッケージング細胞 |
| DE69131908T3 (de) | 1991-02-19 | 2008-04-03 | Oxford Biomedica (Uk) Ltd. | Viruspartikel mit veraendertem wirtspektrum |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| US5821332A (en) † | 1993-11-03 | 1998-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor on the surface of activated CD4+ T-cells: ACT-4 |
| AU7353494A (en) | 1993-11-12 | 1995-05-29 | Case Western Reserve University | Episomal expression vector for human gene therapy |
| US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
| US5759546A (en) | 1994-02-04 | 1998-06-02 | Weinberg; Andrew D. | Treatment of CD4 T-cell mediated conditions |
| US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えｄｎａウイルスおよびその製造方法 |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| US6312700B1 (en) * | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| GB9809951D0 (en) * | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| DE60227067D1 (de) | 2001-05-11 | 2008-07-24 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
| US20040136992A1 (en) * | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
| WO2004035607A2 (en) * | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| JP2007530045A (ja) * | 2004-03-23 | 2007-11-01 | アムジエン・インコーポレーテツド | ヒトｏｘ４０ｌ（ｃｄ１３４ｌ）特異性モノクローナル抗体 |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
-
2006
- 2006-11-24 TW TW095143656A patent/TWI461436B/zh active
- 2006-11-27 PT PT161766175T patent/PT3098238T/pt unknown
- 2006-11-27 FI FIEP17206143.4T patent/FI3345927T3/fi active
- 2006-11-27 AU AU2006318329A patent/AU2006318329B2/en active Active
- 2006-11-27 PL PL17206143.4T patent/PL3345927T3/pl unknown
- 2006-11-27 KR KR1020087012371A patent/KR101340699B1/ko active Active
- 2006-11-27 HU HUE17206143A patent/HUE061960T2/hu unknown
- 2006-11-27 CN CN2006800440857A patent/CN101331150B/zh active Active
- 2006-11-27 JP JP2008542473A patent/JP5476517B2/ja active Active
- 2006-11-27 ES ES06838473T patent/ES2602263T5/es active Active
- 2006-11-27 LT LTEP17206143.4T patent/LT3345927T/lt unknown
- 2006-11-27 EP EP22211094.2A patent/EP4219557A1/en active Pending
- 2006-11-27 US US12/087,436 patent/US8283450B2/en active Active
- 2006-11-27 CA CA2631015A patent/CA2631015C/en active Active
- 2006-11-27 DK DK17206143.4T patent/DK3345927T5/da active
- 2006-11-27 WO PCT/US2006/045522 patent/WO2007062245A2/en not_active Ceased
- 2006-11-27 PL PL06838473.4T patent/PL1951760T5/pl unknown
- 2006-11-27 EP EP06838473.4A patent/EP1951760B2/en active Active
- 2006-11-27 PT PT68384734T patent/PT1951760T/pt unknown
- 2006-11-27 SI SI200632427T patent/SI3345927T1/sl unknown
- 2006-11-27 ES ES16176617.5T patent/ES2667522T3/es active Active
- 2006-11-27 ES ES17206143T patent/ES2938625T3/es active Active
- 2006-11-27 PT PT172061434T patent/PT3345927T/pt unknown
- 2006-11-27 PL PL16176617T patent/PL3098238T3/pl unknown
- 2006-11-27 EP EP16176617.5A patent/EP3098238B1/en active Active
- 2006-11-27 HU HUE06838473A patent/HUE031037T2/en unknown
- 2006-11-27 HU HUE16176617A patent/HUE037642T2/hu unknown
- 2006-11-27 EP EP17206143.4A patent/EP3345927B9/en active Active
-
2012
- 2012-08-31 US US13/601,823 patent/US9475878B2/en active Active
-
2013
- 2013-08-02 JP JP2013161779A patent/JP5802245B2/ja active Active
-
2016
- 2016-09-23 US US15/274,666 patent/US9969810B2/en active Active
-
2018
- 2018-05-14 US US15/979,305 patent/US11192953B2/en active Active
-
2021
- 2021-11-12 US US17/525,512 patent/US12319741B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009518005A5 (OSRAM) | ||
| JP2015504421A5 (OSRAM) | ||
| WO2010095031A3 (en) | Humanized antibodies that bind to cd19 and their uses | |
| RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
| JP2019504032A5 (OSRAM) | ||
| JP2017523786A5 (OSRAM) | ||
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| JP2012532851A5 (OSRAM) | ||
| JP2012511329A5 (OSRAM) | ||
| JP2011526249A5 (OSRAM) | ||
| RU2017137872A (ru) | Композиции для ингибирования masp-2-зависимой активации комплемента | |
| JP2021501566A5 (OSRAM) | ||
| JP2010507594A5 (OSRAM) | ||
| JP2011517447A5 (OSRAM) | ||
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| JP2012525829A5 (OSRAM) | ||
| JP2007510664A5 (OSRAM) | ||
| IL290591B1 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| JP2013198490A5 (OSRAM) | ||
| JP2010535205A5 (OSRAM) | ||
| RU2571204C3 (ru) | Специфические связывающие агенты против в7-н1 | |
| RU2017114341A (ru) | Антитела к pd-l1, связывающие pd-l1 собаки | |
| RU2012112829A (ru) | Анти-gitr-антитела | |
| NZ608660A (en) | Anti-cd48 antibodies and uses thereof | |
| HRP20190008T4 (hr) | Prevencija i liječenje sinukleinopatske i amiloidogene bolesti |